HIV-1 Vaccine Trials Unit (HVTU)

Dr. McElrath is the Principal Investigator of the FHCRC/University of Washington HIV Vaccine Trials Unit (HVTU) research program. The HVTU is one of ten centers nation-wide that is funded to carry out phase I, II, and III HIV vaccine trials to evaluate the safety and efficacy of candidate HIV vaccines. The HVTU has a number of scientific and administrative responsibilities including:

1. Collaboration with the HIV Vaccine Trials Network (HVTN) in the design and development of phase I and II vaccine trial protocols,
2. Participation in the phase I, II, and III clinical trials of candidate HIV vaccines,
3. Recruitment, selection and enrollment of volunteers for the vaccine trials, Immunization and monitoring of volunteers, and organization of follow-up care for enrolled subjects
   
   

Publications:

M.J. McElrath , L. Corey, D. Montefiori, M. Wolff,   D. Schwartz, M. Keefer, R. Belshe, B. Graham, T. Matthews, P. Wright, G. Gorse, R. Dolin, P. Berman, D. Francis, A.M. Duliege, D. Bolognesi, D. Stablein, N. Ketter, P. Fast, and the AIDS Vaccine Evaluation Group.   A phase II study of two HIV-1 gp120 subunit vaccines comparing their immunogenicity and effect on sexual activity in populations at risk for acquiring HIV-1 infection.   AIDS Res Hum Retrovir. 16:907-919, 2000.

F. Hladik, S. Bender, R.E. Akridge, Y.X. Hu, C. Galloway, D. Francis, and M.J. McElrath .   Recombinant HIV-1 glycoprotein 120 induces distinct types of delayed hypersensitivity in persons with or without pre-existing immunologic memory.   J Immunol. 166:3580-3588, 2001.

M. Elizaga and M.J. McElrath.   Progress in the development of a preventive HIV-1 vaccine. Clinics in Lab Med.   22:963-980, 2002.